|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.12 HKD | +1.26% |
|
+4.34% | +18.10% |
| Jun. 29 | Zai Lab Insider Sold Shares Worth $428,545, According to a Recent SEC Filing | MT |
| Jun. 16 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
| Market Cap | 2.3B 18.04B 2.02B 1.87B 1.72B 3.24B 222B 3.28B 22.3B 8.73B 109B 8.64B 8.45B 375B | P/E 2026 * |
-9.25x | P/E 2027 * | -11x |
|---|---|---|---|---|---|
| Enterprise Value | 1.86B 14.57B 1.63B 1.51B 1.39B 2.62B 179B 2.65B 18.01B 7.05B 87.69B 6.97B 6.82B 303B | EV / Sales 2026 * |
4.14x | EV / Sales 2027 * | 3.21x |
| Free-Float |
95.17% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Zai Lab Limited
| 1 day | +1.26% | ||
| 1 week | +4.34% | ||
| Current month | +11.48% | ||
| 1 month | +15.72% | ||
| 3 months | -14.39% | ||
| 6 months | +12.18% | ||
| Current year | +18.10% |
| 1 week | 15.2 |  | 16.5 |
| 1 month | 13.62 | | 16.5 |
| Current year | 12.31 | | 20.42 |
| 1 year | 12.31 | | 32.35 |
| 3 years | 10.56 | | 35.5 |
| 5 years | 10.56 | | 125 |
| 10 years | 10.56 | | 151.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ying Du
CEO | Chief Executive Officer | 61 | 2014-03-31 |
Ya jing Chen
DFI | Director of Finance/CFO | 58 | 2023-07-06 |
Rafael Amado
PSD | President | 62 | 2022-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Ying Du
CHM | Chairman | 61 | 2014-03-31 |
John Diekman
BRD | Director/Board Member | 83 | 2016-12-31 |
Peter Wirth
BRD | Director/Board Member | 75 | 2016-12-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.26% | +4.34% | - | - | 2.3B | |
| +0.45% | +2.91% | +23.77% | -8.09% | 68.69B | |
| -0.37% | +3.10% | +40.83% | +198.45% | 52.97B | |
| +3.72% | +39.50% | +39.50% | +39.50% | 43.61B | |
| -2.83% | -3.13% | -55.32% | -55.71% | 40.75B | |
| +1.61% | +5.84% | +65.60% | -26.59% | 29.99B | |
| +0.29% | -11.54% | +92.64% | -52.81% | 23.67B | |
| +1.50% | +2.18% | +74.22% | +82.99% | 23.45B | |
| +0.11% | -4.95% | +5.31% | +177.86% | 20.46B | |
| +1.20% | +3.20% | +73.91% | +130.23% | 16.66B | |
| Average | +0.60% | +0.98% | +40.05% | +53.98% | 35.58B | |
| Weighted average by Cap. | +0.47% | +1.60% | +32.80% | +47.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 449M 3.52B 393M 364M 335M 632M 43.21B 640M 4.35B 1.7B 21.18B 1.68B 1.65B 73.12B | 596M 4.67B 522M 484M 445M 839M 57.36B 850M 5.77B 2.26B 28.11B 2.24B 2.19B 97.06B |
| Net income | -241M -1.89B -211M -196M -180M -340M -23.2B -344M -2.33B -914M -11.37B -904M -885M -39.26B | -156M -1.23B -137M -127M -117M -221M -15.07B -223M -1.52B -593M -7.39B -587M -575M -25.5B |
| Net Debt | -443M -3.47B -388M -360M -331M -625M -42.68B -632M -4.3B -1.68B -20.92B -1.66B -1.63B -72.22B | -387M -3.04B -339M -314M -289M -546M -37.29B -552M -3.75B -1.47B -18.27B -1.45B -1.42B -63.1B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-22 | HK$16.12 | +1.26% | 4,966,152 |
| 26-07-21 | HK$15.92 | -1.00% | 3,591,400 |
| 26-07-20 | HK$16.08 | +3.74% | 5,697,655 |
| 26-07-17 | HK$15.50 | -4.50% | 8,503,530 |
| 26-07-16 | HK$16.23 | +5.05% | 11,564,600 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZLAB Stock
- 9688 Stock
Select your edition
All financial news and data tailored to specific country editions
